XTX Topco Ltd Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Key Points

• XTX Topco Ltd has acquired a new position in Stoke Therapeutics, purchasing 40,181 shares valued at approximately $267,000.
• Several institutional investors have increased their stakes in Stoke Therapeutics, with GAMMA Investing LLC raising its stake by 1,842.0% in the first quarter.
• Stoke Therapeutics currently holds an average rating of "Buy" from analysts, with a target price ranging from $22.00 to $30.00.

XTX Topco Ltd bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 40,181 shares of the company's stock, valued at approximately $267,000. XTX Topco Ltd owned 0.07% of Stoke Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $133,000. Net Worth Advisory Group bought a new stake in Stoke Therapeutics in the first quarter worth $138,000. Finally, ProShare Advisors LLC bought a new stake in Stoke Therapeutics in the fourth quarter worth $139,000.

Analyst Ratings Changes

STOK has been the topic of several analyst reports. Jefferies Financial Group began coverage on Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $25.80.

Insider Activity

In related news, insider Barry Ticho sold 4,504 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the transaction, the insider directly owned 16,775 shares of the company's stock, valued at $215,055.50. This trade represents a 21.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 12,720 shares of company stock worth $140,095 in the last quarter. Insiders own 9.50% of the company's stock.

Stoke Therapeutics Stock Up 0.5%

Shares of STOK opened at $13.16 on Tuesday. The stock's 50-day moving average price is $12.11 and its 200 day moving average price is $9.99. The firm has a market capitalization of $718.54 million, a price-to-earnings ratio of 16.66 and a beta of 1.15. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $16.15.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.